{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 44,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The chart is a classic waterfall plot used in oncology to show tumor shrinkage/growth.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/17",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.47,
        "x": 0.06,
        "y": 0.298
      },
      "kind": "chart",
      "text": "Response at Variable Dosing",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5773cdea-7060-4f1f-80db-b7971af26e00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.63,
        "y": 0.42
      },
      "kind": "list",
      "text": "A partial response was achieved in the AXL+ NSCLC patient refractory to multiple chemo PKIs and pembrolizumab failure",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "308388c2-8b9b-4832-b8c5-6791ea599405",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.11,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "*1.8mg/kg d1,8 = 2Q3W dosing regimen",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a722cfc5-c2e8-4394-add1-d733d01135ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Encouraging Phase 1 results with Mecbotamab Vedotin (BA3011) in refractory NSCLC patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56d3c287-a510-4afa-bd84-9d7c1b05d322",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "8e687aaa-8c9a-48cc-9ce1-5bf9e561ff21",
      "evidence": "Response at Variable Dosing",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 11,
      "beatId": "9dc7924a-cf61-4c29-9fd6-e666a2b3daec",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "slides 11-21 provide traction information",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e3b4bfda-4f05-4903-9455-c38c0aa043e5",
      "evidence": "slides 11-21 provide data on the effectiveness of CABs",
      "position": 0,
      "objective": "To highlight the potential benefits of CABs in cancer therapy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}